In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.

Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy ...

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Methods Randomised, double-blind, multicentre trial of simvastatin versus placebo in patients undergoing elective oesophagectomy, lobectomy or pneumonectomy at 15 sites throughout the UK. Planned ...

The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

The Health and Human Services Department under Kennedy took unprecedented steps to change how vaccines are evaluated, ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of Novavax (NasdaqGS:NVAX) with a Sell recommendation. Analyst Price Forecast Suggests 141.82% Upside As of June 2, 2025, the ...

Shares of Novavax Inc. NVAX rallied 1.30% to $7.03 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.52% to ...